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Background: The objective of this prospectively randomized phase II trial (Trial registration: EUCTR2004-004007-37-DE)
was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone
(LET) or letrozole and zoledronic acid (LET + ZOL).
Methods: Patients were randomly assigned to receive either LET 2.5 mg/day (n = 79) or the combination of LET
2.5 mg/day and a total of seven infusions of ZOL 4 mg every 4 weeks (n = 89) for 6 months. Primary endpoint was
clinical response rate as assessed by mammogram readings. The study was terminated prematurely due to insufficient
recruitment. We report here on an exploratory analysis of this data.
Results: Central assessment of tumor sizes during the treatment period was available for 131 patients (66 LET, 65
LET + ZOL). Clinical responses (complete or partial) were seen in 54.5% (95% CI: 41.8-66.9) of the patients in the LET arm
and 69.2% (95% CI: 56.6-80.1) of those in the LET + ZOL arm (P = 0.106). A multivariate model showed an OR of 1.72
(95% CI: 0.83-3.59) for the experimental arm.
Conclusion: No increase in the clinical response rate was observed with the addition of ZOL to a neoadjuvant
treatment regimen with LET. However a trend towards a better reponse in the LET + ZOL arm could be observed. This
trend is consistent with previous studies that have investigated the addition of ZOL to chemotherapy, and it may
support the evidence for a direct antitumor action of zoledronic acid.
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Neoadjuvant therapy with either chemotherapy or anti-
hormonal agents has increased the information available
regarding the efficacy of treatment and resistance mecha-
nisms in the primary tumor. While the evidence for the ef-
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reproduction in any medium, provided the orin the neoadjuvant setting is limited the efficacy of these
agents in patients with metastatic and early breast cancer
has been investigated in many studies [1].
In patients with breast cancer metastatic to the bone,
bisphosphonates have been shown to be effective in pre-
venting skeletal-related events, indicating an antitumor
effect [2,3]. In the adjuvant setting, three larger trials
(ABSCG-12, ZO-FAST, and AZURE) have reported a prog-
nostic benefit for at least some subgroups of breast cancer
patients [4-6]. The ABCSG-12 study reported a disease-
free survival (DFS) benefit in a population of premeno-
pausal breast cancer patients when zoledronic acid wasal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that this benefit is greatest in patients over the age of 40,
who achieve a maximal estrogen blockade [5,7]. Similarly,
the ZO-FAST study reported an improvement in DFS in
postmenopausal breast cancer patients [6]. However, this
effect was not observed in the overall population in the
AZURE study [4]. Analysis of the AZURE study raised the
question of which patients are able to benefit most from
treatment with bisphosphonates, as specific subgroups —
such as women with more than 5 years since the end of
the menopause, or women with complete suppression of
ovarian function — were found to experience the greatest
benefit from the addition of zoledronic acid to the standard
treatment [4].
Several mechanisms have been implicated that might
potentially be associated with an antitumor effect of
zoledronic acid; one of these is inhibition of the enzyme
farnesyl diphosphate synthase, which results in altered
synthesis of enzymes such Rho, Rac, and Rab that are
thought to be involved in cell proliferation, cell motility,
angiogenesis, and cell migration [8-15]. It has also been
reported that zoledronic acid blocks the interaction be-
tween mesenchymal stem cells and breast cancer cells,
which is thought to reduce the effect of mesenchymal
stem cells on the progression of breast cancer [16].
On the basis of the findings from clinical studies and
preclinical evidence, it was hypothesized that adding zole-
dronic acid to neoadjuvant treatment with letrozole might
increase the response of primary breast cancer tumors. A
randomized phase II trial was therefore conducted, with
the primary objective being tumor response.
Methods
The trial was conducted in accordance with the
Helsinki Declaration and the International Conference on
Harmonization of Technical Requirements for Registration
of Pharmaceuticals for Human Use (ICH) Harmonized
Tripartite Guidelines for Good Clinical Practice. The study
protocol was approved by the Ethics Committee of the
Medical Faculty, Friedrich-Alexander University Erlangen
Nuremberg (Location of the Principal Investigator),
and in addition by all relevant ethics committees at
each study site, and all of the patients provided written
informed consent.
Patients
This report describes a phase II, multicenter, prospective,
randomized, and controlled open-label trial. Patients had
to be over the age of 18 and had to be postmenopausal as
defined by age over 55; age ≤ 55 years but without a
menstrual period for more than 1 year; or with
luteinizing hormone and follicle-stimulating hormone
levels > 40 IU/L or estradiol levels < 5 ng/dL; or had
to have undergone bilateral oophorectomy before thediagnosis of breast cancer. The invasive breast cancer
must have been histologically confirmed by core needle
biopsy and had to have either a positive estrogen recep-
tor (ER) and/or progesterone receptor (PgR) status,
defined by core biopsy immunohistochemistry with >10%
positive malignant epithelial cells. Clinical Stage had to
be ≥ cT1c (Size ≥1.5 cm) without distant metastases (M0).
Tumors with a size of ≥1.5 cm were allowed as target
lesions, although this size is not considered as a target
lesion according to RECIST criteria [17]. However tumor
size assessments with mammography or breast ultrasound
seem accurate enough to allow tumors of this size for
evaluation [18].
Other inclusion criteria were: adequate renal function
(creatinine clearance >30 mL/minute calculated using the
Cockcroft-Gault equation), adequate bone-marrow func-
tion, adequate hepatic function, life expectancy of at least
12 months, and Eastern Cooperative Oncology Group
(ECOG) status ≤ 2.
Exclusion criteria were: inflammatory breast cancer,
prior letrozole or bisphosphonate treatment; patients with
unstable angina or other uncontrolled cardiac disease;
inflammatory breast cancer, evidence of distant metasta-
ses, other concurrent malignant disease, or current den-
tal problems; and a history of diseases affecting bone
metabolism.Treatment and tumor assessment plan
Patients were randomly assigned to one of the two neoad-
juvant treatment groups — either letrozole 2.5 mg/day
plus a total of seven infusions of zoledronic acid 4 mg
every 4 weeks (LET + ZOL); or letrozole 2.5 mg/day only
(LET) — at a ratio of 1 : 1. Surgery for the breast tumor
and axillary lymph nodes was scheduled 6.5 months after
the patient had received her first dose of the study treat-
ment. Sentinel biopsies were permitted, but complete axil-
lary dissection was mandatory if there were positive
findings. If the tumor progressed during chemotherapy,
the study treatment was discontinued and further treat-
ment was at the discretion of the investigator, who was
the attending physician.
The size of the tumor was assessed before the start of
therapy, after 4 months of treatment, and after 6 months
of treatment, in accordance with our modified response
evaluation criteria (see above). All of the images were read
locally. In order to avoid unblinded reader bias in this
open-label study, a central review of all mammograms
was additionally performed by an independent blinded
radiologist in order to assess the response status of the tar-
get lesion using standardized criteria, as described below.
Principally MRI and ultrasound were allowed assessment
methods as per study protocol but no study site chose
those imaging methods.
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The primary objective of the study was explore whether
the combination of letrozole (2.5 mg/day) and zoledronic
acid (4 mg q4w, or dose-adjusted based on renal function)
is superior to letrozole (2.5 mg/day) monotherapy in rela-
tion to the tumor response after 6 months of preoperative
treatment in postmenopausal patients with primary breast
cancer. “Response” was defined as a complete response
(CR: complete disappearance of all target lesions) or a par-
tial response (PR: at least a 30% decrease in the sum of the
largest diameter of all target lesions), based on MRI or
mammography and/or sonography in accordance with the
modified RECIST criteria [17]. Tumor response evaluation
was performed similar to RECIST, however lesions ≥
1.5 cm as assessed by mammography or ultrasound
were allowed as target lesions. Radiological tumor size
assessment, either by ultrasound or mammography, has
been shown to be very reliable in this range of tumor
sizes [18-20].
Safety was primarily assessed by documentation of ad-
verse events (AEs). The severity of AEs was classified in
accordance with the National Cancer Institute (NCI)
Common Terminology Criteria for Adverse Events (NCI-
CTCAE version 3.0). AEs were documented during the
period from first exposure to the study drug to 30 days
after last exposure to it. Adverse events, whether reported
by the patient, discovered during general questioning by
the investigator, or detected through physical examination,
laboratory tests, or other means, were recorded on the ad-
verse event log in the study case report form and followed
carefully until resolution. It was not mandatory for abnor-
mal laboratory values or test results to be considered AEs
unless they induced clinical signs and symptoms or re-
quired therapeutic interventions. Adverse events were de-
scribed by duration (start and end dates, or at the final
examination if continuing), severity (NCI-CTCAE grades
1–5), relationship to study drug (not suspected, suspected
with letrozole, suspected with zoledronic acid, suspected
with both), and action taken.
Quality of life was assessed using the FACT-B ques-
tionnaire (Functional Assessment of Cancer Therapy-
Breast Cancer). The Quality of life questionnaires should
be completed at each visit (baseline, month 1-6) by the
patient upon arrival at the clinic and before the patient
has either been interviewed by the physician or received
study medication. The FACT-B was analysed in the ITT
population using the ‘data as observed’ by visit as total
score and separated by the sub-scores physical well-
being, social/family well-being, emotional well-being,
functional well-being and breast cancer subscale.
Statistical analysis
Recruitment of a total of 850 patients was planned in order
to reach a power of 80% to demonstrate the superiority ofthe combination therapy (LET +ZOL) in comparison with
letrozole alone (LET) with regard to the response rate after
6 months. A response rate of 35% and an increase in the
response by 10% with the addition of zoledronic acid was
assumed for this calculation. Randomization was strati-
fied by nodal status (N-negative vs. N-positive), tumor
grading (G1 vs. G2–3) and center, and performed within
strata in a 1 : 1 ratio.
A total of 168 patients were enrolled before the study
was terminated due to low recruitment. Given the ori-
ginal assumptions, a figure of 200 patients would result
in a power of only 25%, instead of the required 80%. The
study was therefore grossly underpowered, and the results
of the primary analysis must be regarded as exploratory
rather than confirmatory.
In general, all summary statistics are presented by treat-
ment group (LET vs. LET + ZOL). Categorical variables
are summarized by absolute and relative frequencies.
Continuous variables are summarized by descriptive
statistics of mean, standard deviation, minimum, median,
and maximum. Time-to-event data, including rates of
affected patients, were assessed using Kaplan–Meier
statistics.
A logistic regression model was fitted for the response,
including the dichotomous factors “treatment” (LET vs.
LET + ZOL), “nodal status” (N+ vs. N–), “tumor grading”
(G1 vs. G2 and G3), “tumor size at baseline” (largest diam-
eter ≤ 2 cm vs. > 2 cm) and “age” (< 65 years vs. ≥ 65 years).
The odds ratio (OR) for the combination therapy rela-
tive to the monotherapy was estimated. The difference
between the treatment groups was tested using the like-
lihood ratio test with a two-sided significance level of
5%. P values are presented together with the two-sided
95% confidence intervals (CIs) for the OR.
For six patients in the LET + ZOL arm and two patients
in the LET arm, a response assessment was not available
after 6 months but only after 4 months. For these patients,
it was assumed that the treatment response at that time
would carry forward to the final assessment time point at
6 months (last observation carried forward, LOCF).
All of the statistical analyses were carried out using
SAS version 8.2.
Results
A total of 178 patients were screened for study eligibility
at 27 study sites. Of these, 168 patients were randomized
at 27 centers and received treatment with either letro-
zole monotherapy (LET; n = 79) or combination therapy
with letrozole plus zoledronic acid (LET + ZOL; n = 89).
This population is considered the safety population, in
which toxicity is reported (Figure 1). Tumor measure-
ments, assessed locally, for at least one time point after
the start of treatment were available for 156 patients,
and this population is considered the intention-to-treat
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) diagram. ITT, intention to treat; mITT, modified intention to treat; LET,
letrozole alone; LET + ZOL, letrozole plus zoledronic acid.
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the central reader for 131 patients in the ITT group, and
this population is considered as the modified intention-to-
treat population (mITT, Figure 1). For the per-protocol
(PP) analysis, an additional four patients had to be ex-
cluded (LET: 2; LET + ZOL: 2) from the mITT.
Safety is reported for all patients who started the treat-
ment (safety population) and efficacy is reported for all
patients for whom at least one mammogram was avail-
able for central assessment after the start of treatment
(mITT). For the sensitivity analysis, efficacy data were
analyzed for the PP and ITT populations. Patient and
tumor characteristics for both treatment arms for the
mITT population are summarized in Table 1 for all pa-
tients, and for the safety population in Additional file 1
Table S1.
The patients’ average age was 70.8 years. Most of the
patients (87.7%) had a tumor stage above cT1. As the
enrolled patients represent an older population, most
(86.3%) had a concomitant medical condition — mainly
vascular disorders (56.5%), metabolic and nutritional dis-
orders (32.7%), and musculoskeletal disorders (24.4%).
Efficacy
The primary efficacy variable was tumor response (CR+PR)
after 6 months of neoadjuvant treatment. In the LET-only
arm, there were no clinical complete responses and
36 patients (54.5%) had a partial response. None of
the patients had progressive disease. In the LET + ZOL
arm, there were two patients (3.1%) with a complete re-
sponse and 43 patients (66.2%) with a partial response(Figure 2). One patient (1.5%) was reported to have
progression. With regard to the primary end point, the
response rate in the LET-only arm was therefore
54.5% (95% CI, 41.8 to 66.9), in comparison with
69.2% (95% CI, 56.6 to 80.1) in the LET + ZOL arm.
The P value for the difference was 0.106. However, this
primary analysis was underpowered due to the insufficient
study recruitment. The mean target lesion size (clinically
assessed, longest diameter) decreased by 1.12 cm (±0.92)
from 3.23 cm (±1.19) to 2.12 cm (±1.04) in the LET only
arm and decreased by 1.37 cm (±0.96) from 3.45 cm
(±2.54) cm to 2.08 cm (±2.27) in the LET + ZOL arm.
With regard to histopathological assessment one pa-
tient in the LET + ZOL arm had a regression to a car-
cinoma in situ with no invasive tumor components, and
no pathological complete response was observed. Patho-
logical tumor sizes and pathological ypT classification
are shown in Table 2 for the mITT population and
Additional file 2 Table S2 for the safety population.
In the logistic regression model, none of the covariates
mentioned above (Table 3) was associated with a response.
The analysis showed a trend in favor of the LET + ZOL
treatment (OR = 1.72; 95% CI, 0.827 to 3.586; P = 0.147).
The per-protocol analysis, using central imaging as-
sessments, showed a clinical response in 35 out of 64 pa-
tients (54.7%; 95% CI, 41.7 to 67.2) in the LET-only arm
and in 43 out of 63 patients (68.3%; 95% CI, 55.3 to
79.4) in the LET + ZOL arm (P = 0.145). Using the
tumor assessment at the local study sites (ITT popula-
tion), a response was seen in 26 out of 75 patients
(34.7%; 95% CI, 24.0 to 46.5) in the LET arm and in 37
Table 1 Patient and tumor characteristics for the modified intention-to-treat population
Characteristic LET (n = 66) mean ± SD or
n and %
LET + ZOL (n = 65) mean ± SD or
n and %
Total (n = 131) mean ± SD or
n and %
Age (years)
Mean ± SD 70.6 ± 8.3 71.1 ± 9.1 70.8 ± 8.7
Median (range) 71.0 (54.0–89.0) 70.0 (54.0–88.0) 71.0 (54.0–89.0)
Height (cm)
Mean ± SD 162.3 ± 6.7 162.5 ± 7.0 162.4 ± 6.8
Median (range) 163 (150–185) 163 (144–180) 163 (144–185)
Body weight (kg)
Mean ± SD 70.7 ± 12.9 71.6 ± 16.9 71.2 ± 15.0
Median (range) 69.0 (47.0–114.0) 70.0 (41.0–150.0) 69.2 (41.0–150.0)
BMI (kg/m2)
Mean ± SD 26.9 ± 4.8 27.0 ± 5.8 26.9 ± 5.3
Median (range) 26.3 (17.0–40.4) 26.2 (16.6–55.1) 26.2 (16.6–55.1)
Postmenopausal state: yes 65 (100.0) 66 (100.0) 131 (100.0)
Age group
< 65 years 15 (22.7) 16 (24.6) 31 (23.7)
≥ 65 years 51 (77.3) 49 (75.4) 100 (76.3)
Ethnicity: Caucasian 65 (100.0) 66 (100.0) 131 (100.0)
Histological type
Invasive ductal 44 (66.7) 48 (73.8) 92 (70.2)
Invasive lobular 12 (18.2) 8 (12.3) 20 (15.3)
Invasive ductal and
lobular
2 (3.0) 3 (4.6) 5 (3.8)
Other 8 (12.1) 6 (9.2) 14 (10.7)
Grading
G1 10 (15.2) 10 (15.4) 20 (15.3)
G2 47 (71.2) 46 (70.8) 93 (71.0)
G3 9 (13.6) 8 (12.3) 17 (13.0)
GX 0 (0.0) 1 (1.5) 1 (0.8)
T staging
T in situ 1 (1.5) 0 (0.0) 1 (0.8)
T1 6 (9.1) 5 (7.9) 11 (8.5)
T2 48 (72.7) 40 (63.5) 88 (68.2)
T3 8 (12.1) 8 (12.7) 16 (12.4)
T4 3 (4.5) 10 (15.9) 13 (10.1)
Data lacking 0 2 2
N staging
0 44 (66.7) 36 (55.4) 80 (61.1)
1 20 (30.3) 27 (41.5) 47 (36.0)
2 1 (1.5) 0 (0.0) 1 (0.8)
X 1 (1.5) 2 (3.1) 3 (2.3)
M staging
0 65 (98.5) 65 (100) 130 (99.2)
X 1 (1.5) 0 (0) 1 (0.8)
Data lacking 0
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Table 1 Patient and tumor characteristics for the modified intention-to-treat population (Continued)
Estrogen receptor status
Negative 2 (3.0) 2 (3.1) 4 (3.1)
Positive 64 (97.0) 63 (96.9) 127 (96.9)
Progesterone receptor
status
Negative 7 (10.6) 6 (9.2) 13 (9.9)
Positive 59 (89.4) 59 (90.8) 118 (90.1)
ECOG performance status
0 42 (63.6) 38 (58.5) 80 (61.1)
1 20 (30.3) 24 (36.9) 44 (33.6)
2 4 (6.1) 3 (4.6) 7 (5.3)
3 0 (0) 0 (0.0) 0 (0)
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; LET, letrozole alone; LET + ZOL, letrozole plus zoledronic acid; SD, standard deviation.
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LET + ZOL arm (P = 0.192).
Effect on surgery
A total of 12 patients in the ITT population did not
undergo surgery- Documented primary reasons were
"wish of the patient" (10 patients), "other" (0 patients), and
"inoperable" (2 patients).
A review of the 42 ITT patients who were scheduled
at Baseline to undergo "mastectomy" shows that 13 pa-
tients (31.0%) actually underwent radical mastectomy,
while 6 patients (14.3%) were not operated, 4 patients
(9.5%) were treated with modified radical mastectomy,
18 patients (42.9%) had a lumpectomy/quadrantectomy,
and 1 patient (2.4%) was treated with "other" methods.
The vice versa rates of patients switched from planned
lumpectomy/quadrantectomy to radical and modified
radical mastectomy were 7.9% (n = 9) and 6.1% (n = 7).Figure 2 Primary efficacy analysis: Response Evaluation Criteria in So
partial response) at month 6, based on the central review (modified iNeither treatment arm or other factors such as nodal
status, age, grading or tumor size at baseline were asso-
ciated with type of performed surgery.
Compliance and quality of life
A total of 27 patients (LET: 12; LET + ZOL: 15) discon-
tinued the study prematurely. In the LET arm, this was
due to an unsatisfactory treatment effect (n = 4), an ad-
verse event (n = 1), withdrawal of consent by the patient
(n = 6), and abnormal laboratory values (n = 1). In the
LET + ZOL arm, it was due to an unsatisfactory treat-
ment effect (n = 4), adverse events (n = 6), withdrawal of
consent by the patient (n = 1), abnormal laboratory values
(n = 1), protocol violations (n = 2), and administrative
problems (n = 1).
The mean duration of letrozole administration in the
ITT population (n = 168) was 174.2 ± 39.5 days. Calculating
1 month as 28 days, the median duration of treatment waslid Tumors (RECIST) tumor response rates (complete response +
ntention to treat, last observation carried forward).
Table 2 Tumor characteristics at the time of surgery for
the modified intention to treat population
Characteristic LET (n = 66)
mean ± SD or
n and %
LET + ZOL (n = 65)
mean ± SD or
n and %
Total (n = 131)
mean ± SD
or n and %
Surgery
performed
No 7 (10.6) 3 (4.6) 10 (7.6)
Yes 59 (89.4) 62 (95.4) 121 (92.4)
unknown 0 0 0
pCR
No 59 (100) 62 (100) 121 (100)
Yes 0 (0.0) 0 (0.0) 0 (0.0)
Unknown 7 3 10
ypT
0 0 (0) 0 (0) 0 (0)
is 0 (0) 1 (1.6) 1 (0.8)
1 23 (39.0) 23 (37.1) 46 (38.0)
2 29 (49.2) 28 (45.2) 57 (47.1)
3 6 (10.2) 5 (8.1) 11 (9.1)
4 1 (1.7) 5 (8.1) 6 (5.0)





2.9 (±2.0) 2.7 (±1.7) 2.8 (±1.8)
Table 3 Logistic regression model for predicting tumor
response
n Logistic regression
OR [95% CI] (P value)
Nodal status
N0 51 1 (ref)
N1 80 0.962 [0.446; 2.078] (0.922)
Grading
G2–3 110 1 (ref)
G1 20 1.203 [0.433; 3.339] (0.723)
Baseline tumor size
> 2 cm 16 1 (ref)
≤ 2 cm 114 0.742 [0.242; 2.274] (0.601)
Age
≥ 65 years 100 1 (ref)
< 65 years 31 1.189 [0.483; 2.924] (0.707)
Treatment
LET 65 1 (ref)
LET + ZOL 66 1.722 [0.827; 3.586] (0.147)
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the patients receiving the combination therapy, 70.8%
received all seven (six or more) scheduled infusions. The
mean duration of exposure was 177.2 ± 43.4 days.
The mean baseline total score in the Functional Assess-
ment of Cancer Therapy-Breast (FACT-B) in the ITT
population was 111.4 ± 18.5 score points (median: 115.0,
range: 51.4–141.0), with no relevant differences between
the treatment groups. This baseline score remained stable
over time up to month 6 (with a change by –1.8 ± 13.4
score points). Similarly, the analysis of subscores also did
not show any relevant change during the study period at
any assessment time point.
Safety
A total of 64 patients (81.%) reported Grade 1 or 2 ad-
verse events (AE) in the LET only arm and 78 (87.6%) in
the LET + ZOL arm. With regard to grade 3 or 4 AEs, 7
patients (8.9%) were reported in the LET only arm and
17 patients (19.1%) in the LET + ZOL arm.
Most frequent side effects were musculoskeletal disor-
ders, hot flushes, skin and gastrointestinal disorders. An
overview of AEs is given in Table 4.
Discussion
In this prematurely terminated, randomized phase II study
in postmenopausal women with hormone receptor–posi-
tive primary breast cancer, a positive trend in the clinical
tumor response was observed with the addition of zole-
dronic acid to neoadjuvant treatment with letrozole. This
is to the best of our knowledge the first study in neoadju-
vant breast cancer that has examined the effect of zoledro-
nic acid in addition to endocrine treatment. The study
was terminated due to insufficient recruitment. The treat-
ment was well tolerated and did not affect the patients’
quality of life.
The response rate in the LET-only arm was within the
range of response rates reported in other neoadjuvant
studies that have examined the response to neoadjuvant
therapy with aromatase inhibitors. The response rates in
these studies have varied from 37% to 85% [21-26]. This
wide range reflects a problem that is associated with
conducting neoadjuvant anti-endocrine studies. The
study population is unlikely to achieve a pathological
complete response (pCR), with both chemotherapy and
anti-endocrine therapy. In neoadjuvant anti-endocrine
studies, the clinical response rate (cRR) is therefore used
as an end point [27,28], leading to reduced comparabil-
ity between studies and observers. This can be seen in
the present study as well, as there was a difference be-
tween the central assessment and the local one.
Although the difference between the response rates in
the two treatment arms in the present study was not sig-
nificant, the direction of the observed effect is the same
Table 4 Toxicities according to NCI-CTCAE Version 3.0 in the safety population
LET (n = 79) n (%) LET + ZOL (n = 89) n (%)
Grade 1 and 2 Grade 3 and 4 Grade 1 and 2 Grade 3 and 4
Musculoskeletal and connective tissue disorders 29 (36.7) 2 (2.5) 39 (43.8) 4 (4.5)
Hot flush 25 (31.6) 2 (2.5) 19 (21.3) 0 (0.0)
Skin and subcutaneous tissue disorders 18 (22.8) 0 (0.0) 18 (20.2) 1 (1.1)
Gastrointestinal disorders 16 (20.3) 2 (2.5) 13 (14.6) 2 (2.2)
Infections and infestations 14 (17.7) 1 (1.3) 16 (18.0) 0 (0.0)
Psychiatric disorders 13 (16.5) 2 (2.5) 14 (15.7) 1 (1.1)
Fatigue 12 (15.2) 1 (1.3) 19 (21.3) 1 (1.1)
Nervous system disorders 12 (15.2) 1 (1.3) 18 (20.2) 3 (3.4)
Vertigo and Nausea 11 (13.9) 1 (1.3) 16 (18.0) 2 (2.2)
Cardiac disorders 4 (5.1) 1 (1.3) 4 (4.5) 0 (0.0)
Metabolism and nutrition disorders 4 (5.1) 0 (0.0) 10 (11.2) 0 (0.0)
Respiratory, thoracic and mediastinal disorders 3 (3.8) 1 (1.3) 4 (4.5) 2 (2.2)
Fractures 2 (2.6) 2 (2.5) 0 (0.0) 2 (2.2)
Vomiting 1 (1.3) 0 (0.0) 4 (4.5) 0 (0.0)
Pyrexia 1 (1.3) 0 (0.0) 5 (5.6) 0 (0.0)
Renal and urinary disorders 1 (1.1) 0 (0.0) 5 (6.3) 0 (0.0)
Blood and lymphatic system disorders 0 (0.0) 1 (1.3) 2 (2.2) 1 (1.1)
Hepatobiliary disorders 0 (0.0) 0 (0.0) 1 (1.1) 0 (0.0)
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Zoledronic Acid to Reduce Recurrence (AZURE) study,
the subgroup of neoadjuvantly treated breast cancer pa-
tients was analyzed [29]. In this retrospective and explora-
tory subgroup analysis of 205 patients, the tumor size was
compared between patients who received chemotherapy
(n = 103) and patients who received chemotherapy and
zoledronic acid (n = 102). The tumor size at the time of
surgery was smaller in the zoledronic acid plus chemo-
therapy group than in the chemotherapy-only group. The
residual invasive tumor size (RITS) in the chemotherapy
group was found to be 27.4 mm and the RITS in the
chemotherapy plus zoledronic acid group was found to be
15.5 mm. This difference was statistically significant
(P = 0.006). There was a nonsignificant difference with
regard to the pCR, with 6.9% in the chemotherapy
group and 11.7% in the chemotherapy plus zoledronic
acid group (P = 0.146). The pCR rates are rather low,
but this is representative for this population of patients.
Similarly, a retrospective cohort analysis in breast cancer
patients documented in the M.D. Anderson Cancer
Center database identified 39 patients who were treated
with chemotherapy and neoadjuvant bisphosphonates.
These patients had a pCR in 25.4% of cases, in comparison
with only 16% in the group who did not receive a bisphos-
phonate (P = 0.11) [30]. This difference resulted in an OR
of 2.18 (95% CI, 0.9 to 5.24; P = 0.08) in favor of the group
treated with zoledronic acid. Thus, this study suggests apossible direct antitumor effect of zoledronic acid as
well. In another neoadjuvant trial (NEOZOTAC Trial)
ZOL was added to a taxane, anthracycline and cyclophos-
phamide based chemotherapy. No significant change in
pCR rate could be observed, but a nominal positive effect
could be seen in a subgroup of postmenopausal patients
[31]. Comparable results could be shown in a Japanese
study comparing chemotherapy (FEC100 q3w x4 followed
by weekly paclitaxel for 12 cycles) with or without ZOL.
No significant change in pCR could be reached, but a
trend could be observed in postmenopausal patients with
triple-negative breast cancer [32].
The present study is the first to investigate the addition
of a bisphosphonate to a neoadjuvant endocrine therapy,
showing similar results. As in the other two studies dis-
cussed above, the sample size may have been too low to
detect a statistically significant difference.
The group of patients included was older, with an
average age of 70 years. The group treated may repre-
sent a subset of patients who are thought to be more
susceptible to bisphosphonate treatment than other
subgroups. In addition to the ABSCG-12 trial and the
ZO-FAST trial, which reported a potential anticancer
effect of zoledronic acid [5,6], the AZURE study has also
raised the question of which patients benefit most from
the treatment [4]. The AZURE study included premeno-
pausal and postmenopausal patients who received either
chemotherapy, antihormonal therapy, or both, and they
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acid. There was no difference in the disease-free survival
in the overall study population (HR 0.98; P = 0.79) [4].
However, in patients who were described as having a
low-estrogen environment — defined as either being
aged 60 or older or being at least 5 years past the meno-
pause — a significant improvement in the disease-free
survival was observed [4]. The population included in
the present study fully meets all the criteria for this
subgroup. In addition, the patients in the present study
received antihormonal treatment, which may suppress
any estrogen activity in the tumor even more. It should
be borne in mind that the results should be seen in this
context and that the already weak findings should be
interpreted with caution and only for this subgroup of
patients.
There are some obvious limitations to the study, one
being its premature termination due to insufficient re-
cruitment. The study was designed with an assumed
35% response rate to monotherapy with letrozole; this
expectation in the sample size estimation was clearly
exceeded (54.5%), and the stipulated clinically relevant
difference of 10% in favor of the combination treatment
was met, with a difference in the response rate of 14.7%.
However, statistical significance was not reached, most
likely because of the low sample size resulting from the
insufficient recruitment rate. In addition, as in other
neoadjuvant anti-endocrine studies, the assessment of
the tumor response was not standardized. The response
rates in the local assessment were 34.7% in the LET-only
arm and 45.7% in the LET + ZOL arm, in comparison
with 54.5% and 69.2%, respectively, in the central assess-
ment. Although the effect observed was in the same dir-
ection, the response rate and response rate difference
were smaller in the local assessment. The results thus
reflect the difficulty of assessing the tumor response in
neoadjuvant antihormone therapy studies. However,
sensitivity analyses showed similar effects for all ana-
lyses. Due to rare complete pathological responses after
neoadjuvant anti-endocrine therapy the primary end-
point had to be a clinical one. In our study we did not
see any pCR. Although central assessment was consid-
ered to reduce interobserver variability, a discordance
between the central and the local assessment has to be
mentioned. There were 22 patients for which the local
assessment of a stable disease was changed to partial re-
sponse and there were 8 patients for whom the local as-
sessment of partial response was changed to stable
disease. Other discordances, that would have an effect
on the primary study aim “response” were not made. In
addition to the radiological assessment one could con-
sider the comparison of pathological tumor sizes. No
statistical significant difference was observed concern-
ing this parameter.Conclusions
In summary, this study was unable to show the superiority
of neoadjuvant treatment with letrozole and zoledronic
acid over letrozole-only therapy in relation to the clinical
response rate. Although the study suggests a positive ef-
fect, the number of patients recruited in this prematurely
terminated study was too small for the effect to be shown
to be significant. The early termination of the study is ex-
plained by the difficulty to recruit patients for neoadjuvant
anti-endocrine studies, particularly since novel targeted
therapies are evolving that address the problem of treat-
ment resistance in this group of patients with a generally
low response rate. However, the study results are suggest-
ive of a direct antitumor effect of zoledronic acid.
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